Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) commences share repurchases on October 8, 2018, under the program mandated by the shareholders in the Extraordinary General Meeting held on September 4, 2018. As per the mandate, the company is authorized to purchase not more than CNY 200 million worth of its shares. The repurchase price will be CNY 36.31 per share. The plan is valid for 6 months from the shareholders' approval. On December 24, 2021, the company changed the use of the repurchased shares from used in the company's equity incentive plan" to "cancellation to reduce registered capital".